Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $21.2 million.

  • China SXT Pharmaceuticals' Cash & Equivalents rose 1433.46% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 1433.46%. This contributed to the annual value of $18.1 million for FY2025, which is 4994.62% up from last year.
  • China SXT Pharmaceuticals' Cash & Equivalents amounted to $21.2 million in Q3 2025, which was up 1433.46% from $18.1 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Cash & Equivalents ranged from a high of $31.3 billion in Q3 2021 and a low of $3.0 million during Q3 2022
  • For the 5-year period, China SXT Pharmaceuticals' Cash & Equivalents averaged around $3.1 billion, with its median value being $16.5 million (2022).
  • Per our database at Business Quant, China SXT Pharmaceuticals' Cash & Equivalents surged by 30241681.71% in 2021 and then plummeted by 9999.05% in 2022.
  • Over the past 5 years, China SXT Pharmaceuticals' Cash & Equivalents (Quarter) stood at $31.3 billion in 2021, then tumbled by 99.99% to $3.0 million in 2022, then surged by 284.6% to $11.5 million in 2023, then skyrocketed by 61.47% to $18.5 million in 2024, then grew by 14.33% to $21.2 million in 2025.
  • Its Cash & Equivalents was $21.2 million in Q3 2025, compared to $18.1 million in Q1 2025 and $18.5 million in Q3 2024.